The company receives approval for blood-based test enabling objective differentiation of schizophrenia and bipolar disorder
The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders
Agreement builds on 15 years of successful collaboration between AbbVie and Richter, including globally launched cariprazine products
The move puts a spotlight on one of psychiatry’s most persistent clinical challenges: misdiagnosis and delay
The company doses first patient in US study of Deraphan, as Dolby Ventures joins €53M Series B to support neuropsychiatric innovation
New model focuses on continuity of care, combining therapy, routine and social engagement to support long-term recovery
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones
Subscribe To Our Newsletter & Stay Updated
